SEPTEMBER 26, Cuba’s Biotechnology and Pharmaceutical Industry Group, BioCubaFarma, announced the creation of Innovative Immunotherapy Alliance S.A., the first Cuba-U.S. biotech joint venture, which will be based in the Mariel Special Development Zone.
The joint venture between two renowned research centers – Cuba’s Molecular Immunology Center and the Roswell Park Comprehensive Cancer Center of the United States – marks a historic step in scientific collaboration between the two countries. It will allow for advanced research and development of new cancer drugs, to improve survival rates for thousands of patients in the United States.
The new biotechnology company will include among its products the drug CIMAvax-EGF, a known lung cancer therapy, and three additional immunotherapy treatments for different tumors, developed in Cuba.
In its first years, the venture will have as its main objective the development of scientific and clinical research to demonstrate the safety and effectiveness of these novel treatments in the United States. If these studies are successful, the company will be in a position to export these products for the benefit of U.S. patients, once the necessary licenses have been obtained from the U.S. drug regulatory agency.
Source: BioCubaFarma
